Cartesian Therapeutics Statistics
Total Valuation
RNAC has a market cap or net worth of $229.18 million. The enterprise value is $122.39 million.
| Market Cap | 229.18M |
| Enterprise Value | 122.39M |
Important Dates
The next estimated earnings date is Friday, August 7, 2026, before market open.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RNAC has 29.38 million shares outstanding. The number of shares has increased by 17.02% in one year.
| Current Share Class | 29.38M |
| Shares Outstanding | 29.38M |
| Shares Change (YoY) | +17.02% |
| Shares Change (QoQ) | +3.26% |
| Owned by Insiders (%) | 54.89% |
| Owned by Institutions (%) | 17.05% |
| Float | 10.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 129.11 |
| Forward PS | 373.75 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 68.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.65
| Current Ratio | 7.65 |
| Quick Ratio | 7.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -16.36% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -8.01% |
| Weighted Average Cost of Capital (WACC) | 7.21% |
| Revenue Per Employee | $23,667 |
| Profits Per Employee | -$2.02M |
| Employee Count | 75 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -9.19M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.30% in the last 52 weeks. The beta is 0.61, so RNAC's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -39.30% |
| 50-Day Moving Average | 8.30 |
| 200-Day Moving Average | 7.57 |
| Relative Strength Index (RSI) | 41.02 |
| Average Volume (20 Days) | 136,989 |
Short Selling Information
The latest short interest is 1.93 million, so 6.55% of the outstanding shares have been sold short.
| Short Interest | 1.93M |
| Short Previous Month | 1.89M |
| Short % of Shares Out | 6.55% |
| Short % of Float | 18.11% |
| Short Ratio (days to cover) | 7.04 |
Income Statement
In the last 12 months, RNAC had revenue of $1.78 million and -$151.77 million in losses. Loss per share was -$5.79.
| Revenue | 1.78M |
| Gross Profit | -61.05M |
| Operating Income | -91.32M |
| Pretax Income | -160.97M |
| Net Income | -151.77M |
| EBITDA | -19.39M |
| EBIT | -21.81M |
| Loss Per Share | -$5.79 |
Balance Sheet
The company has $118.64 million in cash and $11.86 million in debt, with a net cash position of $106.79 million or $3.63 per share.
| Cash & Cash Equivalents | 118.64M |
| Total Debt | 11.86M |
| Net Cash | 106.79M |
| Net Cash Per Share | $3.63 |
| Equity (Book Value) | -148.12M |
| Book Value Per Share | -5.19 |
| Working Capital | 106.09M |
Cash Flow
In the last 12 months, operating cash flow was -$72.97 million and capital expenditures -$4.41 million, giving a free cash flow of -$77.37 million.
| Operating Cash Flow | -72.97M |
| Capital Expenditures | -4.41M |
| Depreciation & Amortization | 2.42M |
| Net Borrowing | n/a |
| Free Cash Flow | -77.37M |
| FCF Per Share | -$2.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | -5,144.51% |
| Pretax Margin | -9,068.56% |
| Profit Margin | n/a |
| EBITDA Margin | -1,092.56% |
| EBIT Margin | -1,228.79% |
| FCF Margin | n/a |
Dividends & Yields
RNAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.02% |
| Shareholder Yield | -17.02% |
| Earnings Yield | -66.23% |
| FCF Yield | -33.76% |
Analyst Forecast
The average price target for RNAC is $34.57, which is 343.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $34.57 |
| Price Target Difference | 343.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 104.16% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 5, 2024. It was a reverse split with a ratio of 1:30.
| Last Split Date | Apr 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
RNAC has an Altman Z-Score of -4.45 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.45 |
| Piotroski F-Score | 1 |